07 May 2021 : Clinical Research
Real-World Efficacy of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i) in Heterozygous Familial Hypercholesterolemia Patients Referred for Lipoprotein Apheresis
Anthony Matta123ABCDEF*, Vanina Bongard12ABCDEF, Frédéric Bouisset12ABCDEF, Dorota Taraszkiewicz12ABCDEF, Jean-Pierre Rabès4BDEF, Jean Ferrières12ABCDEFGDOI: 10.12659/MSM.928784
Med Sci Monit 2021; 27:e928784
Table 1 Baseline characteristics of the study population.
| Whole population (n=123) | PCSK9i (n=83) | PCSK9i plus ezetimibe (n=12) | PCSK9i plus statin and ezetimibe (n=28) | |
|---|---|---|---|---|
| Age (years±SD) | 59±11 | 58±12 | 62±11 | 57±10 |
| Sex | ||||
| Male, n (%) | 66 (53.7%) | 41 (49.4%) | 5 (41.7%) | 20 (71.4%) |
| Female, n (%) | 57 (46.3%) | 42 (50.6%) | 7 (58.3%) | 8 (28.6%) |
| Familial hypercholesterolemia, n (%) | 123 (100.0%) | |||
| Without known ASCVD, n (%) | 29 (23.6%) | 25 (30.1%) | 3 (25.0%) | 1 (3.6%) |
| With ASCVD, n (%) | 94 (76.4%) | 58 (69.9%) | 9 (75.0%) | 27 (96.4%) |
| Atherosclerotic disease | ||||
| Coronary artery disease, n (%) | 82 (66.7%) | 50 (60.2%) | 9 (75.0%) | 23 (82.1%) |
| Ischemic stroke, n (%) | 3 (2.4%) | 3 (3.6%) | 0 (0.0%) | 0 (0.0%) |
| Peripheral artery disease, n (%) | 12 (9.8%) | 10 (12.0%) | 0 (0.0%) | 2 (7.1%) |
| Cardiovascular risk factors | ||||
| Hypertension, n (%) | 30 (24.4%) | 21 (25.3%) | 4 (33.3%) | 5 (17.8%) |
| Diabetes mellitus, n (%) | 9 (7.3%) | 7 (8.4%) | 1 (8.3%) | 1 (3.6%) |
| Current smokers, n (%) | 4 (3.3%) | 4 (4.8%) | 0 (0.0%) | 0 (0.0%) |
| Mean total cholesterol level (mg/dl±SD) | 361±83 | 373±83 | 332±66 | 337±82 |
| Mean triglycerides (mg/dl±SD) | 168±69 | 175±73 | 167±59 | 143±52 |
| Mean HDL-c (mg/dl±SD) | 52±13 | 53±14 | 50±10 | 48±13 |
| Mean LDL-c level (mg/dl±SD) | 277±78 | 283±81 | 247±68 | 264±78 |
| ASCVD – atherosclerotic cardiovascular disease; HDL-c – high-density lipoprotein cholesterol; LDL-c – low-density lipoprotein cholesterol; n – number of patients; PCSK9i – proprotein convertase subtilisin/kexin type 9 inhibitors; SD – standard deviation. | ||||